September 7, 2017
Novartis’s erenumab can prevent migraine
Novartis’s AMG 334 (erenumab) for migraine prevention in a second phase study reduced monthly migraine days in patients with chronic…
Pharmaceuticals, Biotechnology and Life Sciences
Tag: Vas Narasimhan
October 8, 2015
Novartis:Long-term efficacy of Gilenya
Novartis has announced a new analysis from the phase III FREEDOMS and FREEDOMS II trials reinforcing the long-term efficacy profile of Gilenya (fingolimod).